Clinical Profile and Determinants of Mortality in Patients with Interstitial Lung Disease Admitted for COVID-19
by
, , , , , , , , , , , ,
Alba Mulet
1,
Iván J. Núñez-Gil
2,
Juan Antonio Carbonell
3,
Joan B. Soriano
4,5,
María C. Viana-Llamas
6,
Sergio Raposeiras-Roubin
7,
Rodolfo Romero
8,
Emilio Alfonso-Rodríguez
9,
Aitor Uribarri
10,
Gisela Feltes
11,
Victor M. Becerra-Muñoz
12,
Francesco Santoro
13,
Martino Pepe
14,
Alex F. Castro-Mejía
15,
David Chipayo
16,
Miguel Corbi-Pascual
17,
Javier López-Pais
18,
Oscar Vedia
19,
Edoardo Manzone
20,
Germán Molina-Romera
21,
Carolina Espejo-Paeres
22,
Álvaro López-Masjuan
23,
Lazar Velicki
24,25
,
Antonio Fernández-Ortiz
2,
Ibrahim El-Battrawy
26,
Jaime Signes-Costa
1,* and add
Show full author list
1
Pulmonary Department, Hospital Clínico Universitario Valencia, INCLIVA, 46010 Valencia, Spain
2
Cardiology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain
3
Bioinformatics and Biostatistics Unit, INCLIVA, 46010 Valencia, Spain
4
Faculty of Medicine, Universitat de les Illes Balears, 07120 Palma, Spain
5
Centro de Investigación en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, 28029 Madrid, Spain
6
Intensive Medicine Department, Hospital Universitario Guadalajara, 19002 Guadalajara, Spain
7
National Center for Cardiovascular Research (CNIC), Department of Cardiology, Álvaro Cunqueiro University Hospital, 36312 Vigo, Spain
8
Emergency Department, Hospital Universitario Getafe, 28905 Madrid, Spain
9
Bellvitge University Hospital, 08907 Barcelona, Spain
10
Cardiology Department, Hospital Clínico Universitario Vall D’Hebrón, 08035 Barcelona, Spain
11
Cardiology Department, Hospital Universitario Vithas Arturo Soria, 28043 Madrid, Spain
12
Cardiology Department, Hospital Clínico Universitario Virgen de la Victoria, 29010 Malaga, Spain
13
Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy
14
Cardiology Department, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, 70124 Bari, Italy
15
Hospital General del Norte de Guayaquil IESS Los Ceibos, Guayaquil 090615, Ecuador
16
Department of Cardiology, Hospital Universitario de Cáceres, 10004 Cáceres, Spain
17
Department of Cardiology, Complejo Hospitalario Universitario de Albacete, 02008 Albacete, Spain
18
Department of Cardiology, Complejo Hospitalario Universitario de Ourense, 32005 Ourense, Spain
19
Instituto de Investigación, Sanitaria del Hospital Clínico San Carlos (IdISSC), Hospital Clínico San Carlos, Universidad Complutense de Madrid, 28040 Madrid, Spain
20
Hospital del Sureste, 28500 Madrid, Spain
21
Department of Preventive Medicine, Hospital Santiago de Compostela, Instituto de Investigaciones Sanitarias de Santiago de Compostela, 15706 A Coruña, Spain
22
Hospital Príncipe Asturias, 28805 Alcalá de Henares, Spain
23
Department of Cardiology, Hospital Universitario Juan Ramon Jimenez, 21005 Huelva, Spain
24
Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia
25
Institute of Cardiovascular Diseases Vojvodina, 21204 Sremska Kamenica, Serbia
26
Department of Cardiology, University Medical Center Mannheim, 68167 Mannheim, Germany
*
Author to whom correspondence should be addressed.
†
Membership of the HOPE Team is provided in the Acknowledgments part.
J. Clin. Med. 2023, 12(11), 3821; https://doi.org/10.3390/jcm12113821
Submission received: 21 March 2023
/
Revised: 19 May 2023
/
Accepted: 30 May 2023
/
Published: 2 June 2023
(This article belongs to the Section Pulmonology)
Abstract
:Background: Concern has risen about the effects of COVID-19 in interstitial lung disease (ILD) patients. The aim of our study was to determine clinical characteristics and prognostic factors of ILD patients admitted for COVID-19. Methods: Ancillary analysis of an international, multicenter COVID-19 registry (HOPE: Health Outcome Predictive Evaluation) was performed. The subgroup of ILD patients was selected and compared with the rest of the cohort. Results: A total of 114 patients with ILDs were evaluated. Mean ± SD age was 72.4 ± 13.6 years, and 65.8% were men. ILD patients were older, had more comorbidities, received more home oxygen therapy and more frequently had respiratory failure upon admission than non-ILD patients (all p < 0.05). In laboratory findings, ILD patients more frequently had elevated LDH, C-reactive protein, and D-dimer levels (all p < 0.05). A multivariate analysis showed that chronic kidney disease and respiratory insufficiency on admission were predictors of ventilatory support, and that older age, kidney disease and elevated LDH were predictors of death. Conclusions: Our data show that ILD patients admitted for COVID-19 are older, have more comorbidities, more frequently require ventilatory support and have higher mortality than those without ILDs. Older age, kidney disease and LDH were independent predictors of mortality in this population.
1. Introduction
The COVID-19 pandemic has affected more than 600 million people around the word, and more than 6 million deaths have been counted to date, according to Johns Hopkins University data [1].
The clinical presentation of COVID-19 has a wide spectrum that ranges from asymptomatic or paucisymptomatic patients to the development of bilateral pneumonia, respiratory failure, respiratory distress and death [2]. The severity of COVID-19’s involvement varies according to the underlying diseases of the patients, among other factors [3].
Interstitial lung diseases (ILDs) are a heterogeneous group of diffuse parenchymal lung disorders with known or unknown causes that lead to inflammation and fibrosis of the alveoli, distal airways and septal interstitium of the lungs [4,5,6,7]. Within the clinical course of an ILD, acute exacerbation can occur at any time, and it is associated with significant morbidity and mortality [8,9,10].
Some studies have shown that the proportion of patients with an ILD is higher among those infected with COVID-19 than in the general population, suggesting that they have a higher susceptibility to infection [11,12]. In addition, patients with ILDs already have impaired lung function, and viral infections are a risk of exacerbation for them [13,14]; thus, it is expected that COVID-19 will have a more severe impact on them.
The aim of this study was to characterize ILD patients admitted for COVID-19 and to determine factors that are associated with a worse prognosis, including either ventilatory support or death.
2. Materials and Methods
2.1. Study Design and Population
Data were obtained from the HOPE (Health Outcome Predictive Evaluation) COVID-19 registry (https://hopeprojectmd.com (accessed on 6 Abril 2020)) on ClinicalTrials.gov (NCT04334291), a multicenter international registry. Patients with ILDs were identified from the cohort. Demographic and clinical data at baseline, upon admission and in-hospital were analyzed.
In brief, the HOPE COVID-19 registry is an international initiative designed as a retrospective cohort registry, with voluntary participation and no financial remuneration. All patients admitted for COVID-19 in one of the participating hospitals were suitable for the study, and researchers followed up until discharge or death. There were no exclusion criteria except for patients’ explicit refusal to participate. From 23 March 2020 to 20 April 2020, all patients fulfilling inclusion criteria from 23 centers in 19 cities and 4 countries (Ecuador, Germany, Italy and Spain) were assessed in the present manuscript.
2.2. Data Extraction
Epidemiological, clinical and outcome data were extracted from electronic medical records. Data were anonymized and stored electronically on a secure, password-protected system. Throat swab samples were obtained from all patients upon admission and tested using real-time reverse transcriptase–polymerase chain reaction assays according to the WHO recommendation. Additionally, data from routine hematological, biochemical and coagulation tests, as well as from chest x-ray and computed tomography reports, were extracted. Comorbidities were evaluated upon admission (including hypertension, dyslipidemia, diabetes mellitus, obesity, current smoking, renal failure, lung disease, cardiac disease, cerebrovascular disease, connective tissue disease, liver disease, cancer, Parkinson’s disease and dementia). All prescribed drugs upon admission were also recorded.
All-cause in-hospital mortality was the primary outcome. Other events were recorded, including invasive mechanical ventilation, non-invasive mechanical ventilation, respiratory insufficiency, heart failure, renal failure, bleeding, sepsis and embolic events. Complications during in-hospital stays were evaluated, including the following: respiratory failure, heart failure, renal failure, pneumonia, sepsis, systemic inflammatory response syndrome (SIRS), clinically relevant bleeding, hemoptysis and embolic events. Definitions of each event can be found at the registry’s website, although final allocation depended on local researchers’ criteria [15,16,17].
2.3. Other Definitions
During laboratory blood testing, levels of C-reactive protein (CRP), procalcitonin, ferritin, D-Dimer, lactate dehydrogenase, troponin, transaminases and triglycerides were defined as elevated according to local laboratory cutoff values. However, suggested values were given as follows: CRP ≥ 10 mg/L, procalcitonin ≥ 0.5 ng/dL, ferritin ≥ 335 ng/mL, D-Dimer ≥ 0.5 mg/dL, troponin (I or T) > 99th percentile, lactate dehydrogenase ≥ 250 U/L, transaminases (aspartate transaminase or glutamate transaminase) ≥ 40 U/L and triglycerides ≥ 200 mg/dL. Lymphopenia was defined as lymphocyte counts < 1000/mm3, and severe lymphopenia was defined as lymphocyte counts < 500/mm3.
2.4. Ethical Considerations
The study was performed according to the ethical principles of the Declaration of Helsinki and Good Clinical Practice Guidelines, and the research protocol was approved by the Ethics Research Committee from the Hospital Clínico San Carlos (Madrid, Spain) (20/241-E) and the Spanish Agency for Medicines and Health Products classification (EPA-0D). Written informed consent was waived due to the characteristics of the anonymized registry and the severity of the situation. However, verbal authorization from the patient (or familiar or caregiver when unavailable) was requested.
2.5. Statistical Analysis
We followed STROBE guidance for observational research [18]. Comparison between groups with or without ILDs was performed according to types of variables. On one hand, for quantitative variables, mean comparisons were conducted by using Student’s t-test if there was normality or the Mann–Whitney test otherwise. Normality was assessed with the Shapiro–Wilks test. On the other hand, comparison of percentages between groups was performed with Fisher’s exact test for dichotomous variables or a chi-square test for contingency tables with more than two categories and if cell count was higher than five.
Logistic regression was carried out to study factors associated with ventilatory support during admission or death. A stepwise approach with a backward–forward method was used to select variables in the multivariable model, and the Akaike information criterion [19] was used as the decision criterion.
Software used for all analysis was R in its 4.0.2 version (R Core Team, 2022). p-values lower than 0.05 were considered statistically significant.
3. Results
From a cohort of 6894 patients admitted for COVID-19, 114 (1.6%) patients with a prior ILD diagnosis were identified [20] and compared with those without ILDs.
The mean (SD) age of ILD patients was 72.4 (13.6) years, and 65.8% were male. Comparing ILD vs non-ILD patients, we found differences in age (72.4 vs. 62.9; p < 0.001) and in a number of comorbidities: hypertension (66.7% vs. 48.1%; p < 0.001), dyslipidemia (50.9 vs. 29.9; p < 0.001), diabetes (34.2 vs. 18.1; p < 0.001), cardiovascular disease (43.9 vs. 20; p < 0.001), obesity (34.2 vs. 18.9; p < 0.001), chronic kidney disease (20.2 vs. 6.3; p < 0.001), cerebrovascular disease (14 vs. 7.4; p = 0.012), connective tissue disease (11.4 vs. 2.3; p < 0.001) and liver disease (9.6 vs. 3.6; p = 0.002). There were also significant differences in frequencies of home oxygen therapy (17.5 vs. 3; p = 0001) and respiratory failure on admission (49.1 vs. 32.3; p < 0.001). Regarding laboratory parameters, there were differences in the percentage of patients with elevated lactate dehydrogenase (LDH) (72.8 vs. 58.9; p = 0.004), elevated C-reactive proteins (88.6 vs. 79.4; p = 0.024) and elevated D-dimers (64.9 vs. 52.4; p < 0.011). Finally, differences were seen in acute kidney injuries during admission (28.1 vs. 14.4; p < 0.001), O2 use during admission (77.2 vs. 67.8; p = 0.034), death during hospitalization (31.6 vs. 18.3; p < 0.001) and death before follow-up (36.8 vs. 19.8; p < 0.001) (Table 1).
Causes of death during admission were analyzed to identify differences between patients with ILDs vs. those without. Death from respiratory causes was much more frequent in patients with ILDs (20% vs. 9.8%) (Table 2).
Within the group of patients with ILDs, a bivariate and multivariable logistic regression was performed to predict those characteristics of the patients that were related to the need for ventilatory support (high-flow nasal cannula or invasive or non-invasive mechanical ventilation) during admission. We found that chronic kidney disease (OR: 5.63 95% CI: 1.50–26.99; p 0.017) and the presence of respiratory failure on admission (OR: 11.21 95% CI: 2.85–75,24; p 0.002) were associated with the need for ventilatory support during hospitalization (Table 3).
Finally, we performed a bivariate and multivariable logistic regression to predict death in ILD patients admitted for COVID-19 (Table 4). We identified associations with the following variables: older age (OR: 1.09 95% CI: 1.04–1.15; p < 0.001), chronic kidney disease (OR: 6.22 95% CI: 1.48–31.39; p = 0.017), LDH elevation OR: 7.65 95% CI: 1.85–43.10; p = 0.010) and acute kidney failure during admission (OR: 4.20 95% CI: 1.30–14.41; p = 0.018).
Mean comparison was carried out using Student’s t-test in the presence of normality, and if the data was non-normal, the Mann–Whitney U test was used instead. For quality variables, the comparison of percentages between groups was carried out using Fisher’s exact test for dichotomous variables or a chi-square test for contingency tables with more than two categories if the cell count was higher than five.
A combined cause of death is defined as when several of the factors described previously caused the death of the patient, and it was not possible to identify one as the only one.
4. Discussion
In our multicenter international prospective study, ILD patients admitted for COVID-19 were older, had more comorbidities, required more ventilatory support during admission and had worse prognoses than non-ILD patients. As seen in other patients with COVID-19, renal failure, whether acute or chronic [21,22], contributes to more severe infections and even increases the risk of death in ILD patients. Moreover, older age and elevated LDH on admission were able to predict death in those patients.
ILD patients are particularly susceptible to respiratory infections. To begin with, they are patients who, in many cases, suffer from a functional limitation in their lungs. Further, it has been described that viral infections can trigger an exacerbation of ILDs [23,24], which would aggravate any established or in-development COVID-19-based pneumonia.
In our cohort, we saw that ILD patients have certain baseline aspects that differentiate them. For instance, patients with ILDs are older, as these diseases are associated with advanced age [25,26], such as idiopathic pulmonary fibrosis, the most frequent ILD [27]. We also report that ILD patients more frequently have comorbidities, as they are usually more complex patients, which also contributes to a worse prognosis; they also more frequently present elevated inflammatory reactants in blood or serum.
Many ILD patients suffer respiratory failure and are on home oxygen therapy, which contributes to the fact that they more frequently arrive at the hospital with respiratory insufficiency and require ventilatory support during hospitalization.
Finally, in these patients, we found independent determinants that predict a higher risk of death, such as the presence of acute or chronic renal failure, older age and elevated LDH. These factors should be flagged upon admission to diminish the risk of any fatal outcome. In addition, we report that ILD patients die more frequently from respiratory causes compared to non-ILD patients (Table 2).
As previously presented [28], patients suffering from any lung diseases had worse 30-day survival than those without a prior history of lung disease. A sub-analysis of each lung disease showed that COPD and ILD had the worse survival of these patients. In the current study, this was further confirmed for ILD patients, who presented specific features. Therefore, our results are consistent with other published cohort studies of patients with ILD: these patients have a more severe form of SARS-CoV-2 infection and COVID-19 as well as higher mortality [29].
We previously reported that patients with COVID-19 have elevated serum biomarkers involved in pulmonary fibrosis [30], and other studies have demonstrated the fibrotic sequelae that COVID-19 can leave behind [31], which could contribute to worsening the underlying disease in these patients who already have interstitial involvement prior to infection.
The strengths of our study are that this is an international multicenter study with a large sample size, and it represents real-world data. However, our study has several limitations to consider. First, we did not analyze individual types of ILDs, which may encompass a broad spectrum of diagnoses with different prognoses. Second, we did not take into account the immunosuppressive medication that each patient was receiving or the data from their pulmonary function tests, which are variables that could influence patient prognoses. Furthermore, the confidence intervals are wide, mainly due to the small sample size of ILD patients. In addition, this was a multicenter study conducted during the first wave of the COVID-19 pandemic, which may have contributed to missing data on key variables that were not collected and were not taken into account in the statistical analysis.
5. Conclusions
Patients with ILDs admitted for COVID-19 pneumonia were older and had more comorbidities than those without ILDs. During admission, these patients more frequently required ventilatory support and were more likely to have a fatal outcome, with the most likely cause of death being respiratory failure. It is paramount to recognize them upon admission, as they are at elevated risk for several complications and death.
Author Contributions
All authors contributed to the data collection, critical revision of the article and final approval of the version to be published. Conception or design of the work and data analysis and interpretation: A.M. and J.S.-C. Drafting the article: A.M. and J.S.-C. Patients were not involved in the design of the study. All authors have read and agreed to the published version of the manuscript.
Funding
Non conditioned grant (Fundación Interhospitalaria para la Investigación cardiovascular, FIC. Madrid, Spain). This nonprofit institution had no role in the study design; collection, analysis, interpretation of data; in the writing of the report; nor in the decision to submit the paper for publication.
Institutional Review Board Statement
Our study was performed in accordance with the ethical standards of our institutional (Hospital Clinico San Carlos, Spain) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
Not applicable.
Acknowledgments
To all HOPE COVID-19 investigators, scientific committees and collaborators.
Conflicts of Interest
The authors declare no conflict of interest.
References
- COVID-19 Map. Johns Hopkins Coronavirus Resource Center. Available online: https://coronavirus.jhu.edu/map.html (accessed on 26 October 2022).
- Guan, W.J.; Ni, Z.Y.; Hu, Y.; Liang, W.H.; Ou, C.Q.; He, J.X.; Liu, L.; Shan, H.; Lei, C.L.; Hui, D.S.C.; et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020, 382, 1708–1720. [Google Scholar] [CrossRef] [PubMed]
- Banerjee, A.; Pasea, L.; Harris, S.; Gonzalez-Izquierdo, A.; Torralbo, A.; Shallcross, L.; Noursadeghi, M.; Pillay, D.; Sebire, N.; Holmes, C.; et al. Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: A population-based cohort study. Lancet 2020, 395, 1715–1725. [Google Scholar] [CrossRef]
- Travis, W.D.; Costabel, U.; Hansell, D.M.; King, T.E.; Lynch, D.A.; Nicholson, A.G.; Ryerson, C.J.; Ryu, J.H.; Selman, M.; Wells, A.U.; et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013, 188, 733–748. [Google Scholar] [CrossRef]
- Raghu, G.; Remy-Jardin, M.; Richeldi, L.; Thomson, C.C.; Inoue, Y.; Johkoh, T.; Kreuter, M.; Lynch, D.A.; Maher, T.M.; Martinez, F.J.; et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2022, 205, e18–e47. [Google Scholar] [CrossRef] [PubMed]
- Mueller-Mang, C.; Ringl, H.; Herold, C. Interstitial Lung Diseases. In Multislice CT; Springer: Berlin/Heidelberg, Germany, 2017; pp. 261–288. [Google Scholar]
- Griese, M. Etiologic Classification of Diffuse Parenchymal (Interstitial) Lung Diseases. J. Clin. Med. 2022, 11, 1747. [Google Scholar] [CrossRef] [PubMed]
- Kim, D.S.; Park, J.H.; Park, B.K.; Lee, J.S.; Nicholson, A.G.; Colby, T. Acute exacerbation of idiopathic pulmonary fibrosis: Frequency and clinical features. Eur. Respir. J. 2006, 27, 143–150. [Google Scholar] [CrossRef] [Green Version]
- Song, J.W.; Hong, S.B.; Lim, C.M.; Koh, Y.; Kim, D.S. Acute exacerbation of idiopathic pulmonary fibrosis: Incidence, risk factors and outcome. Eur. Respir. J. 2011, 37, 356–363. [Google Scholar] [CrossRef]
- Tachikawa, R.; Tomii, K.; Ueda, H.; Nagata, K.; Nanjo, S.; Sakurai, A.; Otsuka, K.; Kaji, R.; Hayashi, M.; Katakami, N.; et al. Clinical Features and Outcome of Acute Exacerbation of Interstitial Pneumonia: Collagen Vascular Diseases-Related versus Idiopathic. Respiration 2012, 83, 20–27. [Google Scholar] [CrossRef]
- Lee, H.; Choi, H.; Yang, B.; Lee, S.K.; Park, T.S.; Park, D.W.; Moon, J.-Y.; Kim, T.-H.; Sohn, J.W.; Yoon, H.J.; et al. Interstitial lung disease increases susceptibility to and severity of COVID-19. Eur. Respir. J. 2021, 58, 2004125. [Google Scholar] [CrossRef]
- Drake, T.M.; Docherty, A.B.; Harrison, E.M.; Quint, J.K.; Adamali, H.; Agnew, S.; Babu, S.; Barber, C.M.; Barratt, S.; Bendstrup, E.; et al. Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. Am. J. Respir. Crit. Care Med. 2020, 202, 1656–1665. [Google Scholar] [CrossRef]
- Leuschner, G.; Behr, J. Acute Exacerbation in Interstitial Lung Disease. Front. Med. 2017, 4, 176. [Google Scholar] [CrossRef] [Green Version]
- Collard, H.R.; Ryerson, C.J.; Corte, T.J.; Jenkins, G.; Kondoh, Y.; Lederer, D.J.; Lee, J.S.; Maher, T.M.; Wells, A.U.; Antoniou, K.M.; et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am. J. Respir. Crit. Care Med. 2016, 194, 265–275. [Google Scholar] [CrossRef] [PubMed]
- Rivera-Caravaca, J.M.; Núñez-Gil, I.J.; Vivas, D.; Viana-Llamas, M.C.; Uribarri, A.; Becerra-Muñoz, V.M.; Uribarri, A.; Romero, R.; García-Aguado, M.; Fernández-Rozas, I.; et al. Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID-19. Eur. J. Clin. Investig. 2021, 51, e13436. [Google Scholar] [CrossRef]
- Espejo-Paeres, C.; Núñez-Gil, I.J.; Estrada, V.; Fernández-Pérez, C.; Uribe-Heredia, G.; Cabré-Verdiell, C.; Uribarri, A.; Romero, R.; García-Aguado, M.; Fernández-Rozas, I.; et al. Impact of smoking on COVID-19 outcomes: A HOPE Registry subanalysis. BMJ Nutr. Prev. Health 2021, 4, 285–292. [Google Scholar] [CrossRef]
- Ruiz-Sánchez, J.G.; Núñez-Gil, I.J.; Cuesta, M.; Rubio, M.A.; Maroun-Eid, C.; Arroyo-Espliguero, R.; Romero, R.; Becerra-Muñoz, V.M.; Uribarri, A.; Feltes, G.; et al. Prognostic Impact of Hyponatremia and Hypernatremia in COVID-19 Pneumonia. A HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19) Registry Analysis. Front. Endocrinol. 2020, 11, 599255. [Google Scholar] [CrossRef]
- von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gøtzsche, P.C.; Vandenbroucke, J.P.; Initiative, S. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Lancet 2007, 370, 1453–1457. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Akaike, H. Information Theory and an Extension of the Maximum Likelihood Principle. In Selected Papers of Hirotugu Akaike; Springer Series in Statistics; Parzen, E., Tanabe, K., Kitagawa, G., Eds.; Springer: New York, NY, USA, 1998; pp. 199–213. [Google Scholar] [CrossRef]
- Gil, I.J.N. International COVID-19 Clinical Evaluation Registry: HOPECOVID-19. (Health Outcome Predictive Evaluation for COVID-19); 2022. Report No.: NCT04334291. Available online: https://clinicaltrials.gov/ct2/show/NCT04334291 (accessed on 9 January 2023).
- Pecly, I.M.D.; Azevedo, R.B.; Muxfeldt, E.S.; Botelho, B.G.; Albuquerque, G.G.; Diniz, P.H.P.; Silva, R.; Rodrigues, C.I.S. COVID-19 and chronic kidney disease: A comprehensive review. J. Bras. Nefrol. 2021, 43, 383–399. [Google Scholar] [CrossRef]
- Hippisley-Cox, J.; Coupland, C.A.; Mehta, N.; Keogh, R.H.; Diaz-Ordaz, K.; Khunti, K.; Lyons, R.; Kee, F.; Sheikh, A.; Rahman, S.; et al. Risk prediction of COVID-19 related death and hospital admission in adults after COVID-19 vaccination: National prospective cohort study. BMJ 2021, 374, n2244. [Google Scholar] [CrossRef]
- Britto, C.J.; Brady, V.; Lee, S.; Dela Cruz, C.S. Respiratory Viral Infections in Chronic Lung Diseases. Clin. Chest Med. 2017, 38, 87–96. [Google Scholar] [CrossRef] [PubMed]
- On, R.; Matsumoto, T.; Kushima, H.; Hirano, R.; Fujita, M. Prevalence of viral infection in acute exacerbation of interstitial lung diseases in Japan. Respir. Investig. 2020, 58, 473–478. [Google Scholar] [CrossRef]
- Khanna, D.; Tashkin, D.P.; Denton, C.P.; Renzoni, E.A.; Desai, S.R.; Varga, J. Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. Am. J. Respir. Crit. Care Med. 2020, 201, 650–660. [Google Scholar] [CrossRef] [PubMed]
- Liu, R.M.; Liu, G. Cell senescence and fibrotic lung diseases. Exp. Gerontol. 2020, 132, 110836. [Google Scholar] [CrossRef] [PubMed]
- Sauleda, J.; Núñez, B.; Sala, E.; Soriano, J.B. Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes. Med. Sci. 2018, 6, 110. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Signes-Costa, J.; Núñez-Gil, I.J.; Soriano, J.B.; Arroyo-Espliguero, R.; Eid, C.M.; Romero, R.; Uribarri, A.; Fernández-Rozas, I.; Aguado, M.G.; Becerra-Muñoz, V.M.; et al. Prevalence and 30-Day Mortality in Hospitalized Patients with COVID-19 and Prior Lung Diseases. Arch. Bronconeumol. 2021, 57, 13–20. [Google Scholar] [CrossRef] [PubMed]
- Martínez-Besteiro, E.; Molina-Molina, M.; Gaeta, A.M.; Aburto, M.; Casanova, Á.; Rigual Bobillo, J.; Orozco, S.; Rojo, R.P.; Godoy, R.; Ballesteros, B.L.-M.; et al. Impact of COVID-19 Infection on Patients with Preexisting Interstitial Lung Disease: A Spanish Multicentre Study. Arch. Bronconeumol. 2023, 59, 273–276. [Google Scholar] [CrossRef] [PubMed]
- Safont, B.; Tarraso, J.; Rodriguez-Borja, E.; Fernández-Fabrellas, E.; Sancho-Chust, J.N.; Molina, V.; Lopez-Ramirez, C.; Lope-Martinez, A.; Cabanes, L.; Andreu, A.L.; et al. Lung Function, Radiological Findings and Biomarkers of Fibrogenesis in a Cohort of COVID-19 Patients Six Months after Hospital Discharge. Arch. Bronconeumol. 2022, 58, 142–149. [Google Scholar] [CrossRef]
- Ambardar, S.R.; Hightower, S.L.; Huprikar, N.A.; Chung, K.K.; Singhal, A.; Collen, J.F. Post-COVID-19 Pulmonary Fibrosis: Novel Sequelae of the Current Pandemic. J. Clin. Med. 2021, 10, 2452. [Google Scholar] [CrossRef]
Table 1.
Study patient characteristics.
| ILD Patients n = 114 | Non-ILD Patients n = 6840 | Total n = 6954 | p-Value | |
|---|---|---|---|---|
| Age, years | 72.4 (13.6) | 62.9 (18) | 63.1 (18) | <0.001 |
| Male sex | 75 (65.8%) | 4009 (58.6%) | 83 (61.5%) | 0.148 |
| Current smoker | 6 (5.3) | 433 (6.3) | 439 (6.3) | 0.757 |
| Comorbidities | ||||
| Hypertension | 76 (66.7%) | 3287 (48.1) | 3363 (48.4) | <0.001 |
| Dyslipidemia | 58 (50.9%) | 2044 (29.9%) | 2102 (30.0%) | <0.001 |
| Diabetes | 39 (34.2%) | 1237 (18.1%) | 1276 (18.3%) | <0.001 |
| Cardiovascular disease | 50 (43.9%) | 1367 (20%) | 1417 (20.4%) | <0.001 |
| Obesity | 39 (34.2) | 1293 (18.9) | 1332 (19.2) | <0.001 |
| Chronic kidney disease | 23 (20.2) | 430 (6.3) | 453 (6.5) | <0.001 |
| Cerebrovascular disease | 16 (14.0) | 503 (7.4) | 519 (7.5) | 0.012 |
| Connective tissue disease | 13 (11.4) | 159 (2.3) | 172 (2.5) | <0.001 |
| Liver disease | 11 (9.6) | 247 (3.6) | 258 (3.7) | 0.002 |
| Home oxygen therapy | 20 (17.5) | 203 (3) | 223 (3.2) | <0.001 |
| Respiratory insufficiency on admission | 56 (49.1) | 2210 (32.3) | 2266 (32.6) | <0.001 |
| † Laboratory findings | ||||
| Lymphocytes, ×109/L | 1373.5 (2542.1) | 1401.8 (2616.2) | 1401.3 (2614.8) | 0.912 |
| Elevated LDH | 83 (72.8) | 4027 (58.9) | 4110 (59.1) | 0.004 |
| Elevated C-reactive proteins | 101 (88.6) | 5430 (79.4) | 5531 (79.5) | 0.024 |
| Elevated D-dimers | 74 (64.9) | 3583 (52.4) | 3657 (52.6) | 0.011 |
| Acute kidney failure during admission | 32 (28.1) | 984 (14.4) | 984 (14.4) | <0.001 |
| O2 used during admission | 88 (77.2) | 4636 (67.8) | 4724 (67.9) | 0.034 |
| Death during hospitalization | 36 (31.6%) | 1252 (18.3%) | 1288 (18.5%) | <0.001 |
| Death before follow-up | 42 (36.8%) | 1351 (19.8%) | 1393 (20.0%) | <0.001 |
Data are expressed as n (%) or mean (SD). ILD, interstitial lung disease; LDH, lactate dehydrogenase. † All laboratory findings are peak values except for lymphocytes, in which the lowest value is given.
Table 2.
Causes of death.
| ILD Patients n = 114 | Non-ILD Patients n = 6840 | Total n = 6954 | p-Value | |
|---|---|---|---|---|
| Combined | 5 (4.4%) | 267 (3.9) | 272 (3.9) | <0.001 |
| Respiratory | 23 (20.2%) | 667 (9.8%) | 690 (9.9%) | |
| Sepsis | 3 (2.6%) | 83 (1.2%) | 86 (1.2%) | |
| SIRS | 1 (0.9%) | 45 (0.7%) | 46 (0.7%) | |
| Renal Failure | 2 (1.8%) | 8 (0.1%) | 10 (0.1%) | |
| Cardiovascular | 0 (0%) | 46 (0.7%) | 46 (0.7%) | |
| Cerebrovascular | 0 (0%) | 22 (0.3%) | 22 (0.3%) | |
| Other | 0 (0%) | 48 (0.7%) | 48 (0.7%) |
ILD, interstitial lung disease.
Table 3.
Bivariate and multivariable logistic regression to predict need for ventilatory support during admission.
Table 3.
Bivariate and multivariable logistic regression to predict need for ventilatory support during admission.
| Ventilatory Support During Admission * | Bivariate Analysis | Multivariable Analysis | ||||
|---|---|---|---|---|---|---|
| Yes | No | OR (95% CI) | p-Value | OR (95% CI) | p-Value | |
| Male gender | 30 (40) | 45 (60) | 1.28 (0.57–2.95) | 0.55 | ||
| Age | 74.3 (11.2) | 71.2 (15) | 1.02 (0.99–1.05) | 0.254 | ||
| Hypertension | 30 (40) | 45 (60) | 1.28 (0.57–2.95) | 0.55 | ||
| Diabetes mellitus | 13 (33.3) | 26 (66.7) | 0.80 (0.34–2.79) | 0.587 | ||
| Obesity | 14 (35.9) | 25 (64.1) | 0.87 (0.38–1.93) | 0.732 | ||
| Smoker | 1 (16.7) | 5 (83.3) | 0.31 (0.02–2.00) | 0.29 | 0.26 (0.01–3.87) | 0.36 |
| Chronic kidney disease | 13 (56.5) | 10 (43.5) | 2.60 (1.03–6.76) | 0.045 | 5.63 (1.50–26.99) | 0.017 |
| Heart disease | 20 (40) | 30 (60) | 1.16 (0.54–2.49) | 0.704 | ||
| Connective tissue disease | 2 (15.4) | 11 (84.6) | 0.26 (0.04–1.04) | 0.092 | 0.27 (0.03–1.38) | 0.149 |
| Elevated PCR | 39 (39) | 61 (61) | 1.44 (0.44–5.60) | 0.567 | ||
| Elevated LDH | 37 (45.1) | 45 (54.9) | 3.43 (1.34–10.02) | 0.015 | 2.84 (0.83–11.23) | 0.109 |
| Lymphocyte count | 1477.9 (3776.3) | 1326.9 (1464.8) | 1.00 (1.00–1.00) | 0.77 | ||
| Respiratory insufficiency on admission | 41 (51.2) | 39 (48.8) | 16.29 (4.51–104.90) | <0.001 | 11.21 (2.85–75.24) | 0.002 |
| Acute kidney failure during admission | 17 (53.1) | 15 (46.9) | 1.28 (0.57–2.95) | 0.04 | ||
* Ventilatory support = high-flow nasal cannula or mechanical ventilation (invasive or non-invasive). Variable selection for multivariable model done according to the Akaike information criterion.
Table 4.
Bivariate and multivariable logistic regression to predict death.
| Death During Admission * | Bivariate Analysis | Multivariable Analysis | ||||
|---|---|---|---|---|---|---|
| Yes | No | OR (95% CI) | p-Value | OR (95% CI) | p-Value | |
| Male gender | 26 (34.7) | 49 (65.3) | 0.76 (0.34–0.1.70) | 0.505 | 0.32 (0.10–0.97) | 0.05 |
| Age | 78.2 (10.9) | 69.3 (14) | 1.07 (1.03–1.11) | 0.001 | 1.09 (1.04–1.15) | <0.001 |
| Hypertension | 31 (40.8) | 45 (59.2) | 1.69 (0.74–4.02) | 0.219 | ||
| Diabetes mellitus | 14 (35.9) | 25 (64.1) | 0.97 (0.42–2.17) | 0.94 | ||
| Obesity | 0.02 (−0.14–0.19) | 0.767 | 0.08 (−0.06–0.22) | 0.241 | ||
| Smoker | 3 (50) | 3 (50) | 1.63 (0.29–9.21) | 0.561 | 3.40 (0.29–41.99) | 0.326 |
| Chronic kidney disease | 15 (65.2) | 8 (34.8) | 4.44 (1.73–12.22) | 0.003 | 6.22 (1.48–31.39) | 0.017 |
| Heart disease | 23 (46.0) | 27 (54.0) | 2.02 (0.94–4.41) | 0.075 | ||
| Connective tissue disease | 4 (30.8) | 9 (69.2) | 0.74 (0.19–2.43) | |||
| Elevated PCR | 38 (37.6) | 63 (62.4) | 0.10 (−0.15–0.34) | 0.429 | 1.36 (0.41–5.29) | 0.631 |
| Elevated LDH | 35 (42.2) | 48 (57.8) | 2.50 (1.01–6.87) | 0.058 | 7.65 (1.85–43.10) | 0.01 |
| Lymphocyte count | 1222.7 (1751.2) | 1453.2 (2882.5) | 1.00 (1.00–1.00) | 0.663 | ||
| Respiratory insufficiency on admission | 35 (43.8) | 45 (56.2) | 2.89 (1.17–7.92) | 0.028 | ||
| Acute kidney failure during admission | 20 (62.5) | 12 (37.5) | 4.47 (1.91–10.91) | 0.001 | 4.20 (1.30–14.41) | 0.018 |
| Thromboembolic event | 3 (60.0) | 2 (40.0) | 2.65 (0.42–20.80) | 0.296 | ||
* Mean (SD) or n (%) as appropriate. LDH, lactate dehydrogenase. Variable selection for multivariable model done according to the Akaike information criterion.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Mulet, A.; Núñez-Gil, I.J.; Carbonell, J.A.; Soriano, J.B.; Viana-Llamas, M.C.; Raposeiras-Roubin, S.; Romero, R.; Alfonso-Rodríguez, E.; Uribarri, A.; Feltes, G.; et al. Clinical Profile and Determinants of Mortality in Patients with Interstitial Lung Disease Admitted for COVID-19. J. Clin. Med. 2023, 12, 3821. https://doi.org/10.3390/jcm12113821
AMA Style
Mulet A, Núñez-Gil IJ, Carbonell JA, Soriano JB, Viana-Llamas MC, Raposeiras-Roubin S, Romero R, Alfonso-Rodríguez E, Uribarri A, Feltes G, et al. Clinical Profile and Determinants of Mortality in Patients with Interstitial Lung Disease Admitted for COVID-19. Journal of Clinical Medicine. 2023; 12(11):3821. https://doi.org/10.3390/jcm12113821
Chicago/Turabian StyleMulet, Alba, Iván J. Núñez-Gil, Juan Antonio Carbonell, Joan B. Soriano, María C. Viana-Llamas, Sergio Raposeiras-Roubin, Rodolfo Romero, Emilio Alfonso-Rodríguez, Aitor Uribarri, Gisela Feltes, and et al. 2023. "Clinical Profile and Determinants of Mortality in Patients with Interstitial Lung Disease Admitted for COVID-19" Journal of Clinical Medicine 12, no. 11: 3821. https://doi.org/10.3390/jcm12113821
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
